Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China

doi:10.3748/wjg.v26.i30.4465

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 30

This Article

(278)

(297)

(0)

(24)

(1)

(9812)

(42)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Study

World J Gastroenterol. Aug 14, 2020; 26(30): 4465-4478
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4465

Table 3 Efficacy of lenvatinib in patients with advanced hepatocellular carcinoma

Investigator review according to RECIST 1.1	ALL (n = 54)	HBV-related HCC (n = 40)	P value
Progression-free survival (d, 95%CI)	168 (130-205)	175 (124-226)	0.250
Time to progression (d, 95%CI)	153 (116-189)	156 (126-186)	0.520
Objective response	22%	25%	0.753
Complete response	0	0	-
Partial response	12	10	-
Stable disease	36	26	0.866
Progressive disease	6	4	-
Disease control rate	88%	90%	0.863
Decreased AFP predicts tumor reduction
Se	56.7%	53.8%	-
Sp	83.3%	85.7%	-

HBV: Hepatitis B virus; RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1; AFP: Alpha-fetoprotein; Se: Sensitivity; Sp: Specificity; CI: Confidence interval.

Full Size Table

Citation: Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478
URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4465.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4465

Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478 [PMID: 32874058 DOI: 10.3748/wjg.v26.i30.4465]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.